布拉迪基宁的新陈代谢和药物诱导的血管
Sylwia Smolinska1, Darío Antolín-Amérigo2, Florin-Dan Popescu3
1Department of Clinical Immunology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
International journal of molecular sciences
|July 29, 2023
概括
没有疹的药物诱发性血管 (AE) 与布拉迪基宁 (BK) 代谢有关. 某些心血管和糖尿病药物可以通过影响BK分解和受体引起BK介导的AE.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 心血管医学 心血管医学
背景情况:
- 布拉迪基宁 (BK) 和其受体是血管 (AE) 发病的关键.
- 没有疹的药物诱导性血管 (AE) 涉及改变的BK代谢.
- 涉及各种药物,包括心血管和抗糖尿病药物.
研究的目的:
- 阐明BK代谢和受体在药物诱导的AE中的作用.
- 确定与BK介导AE相关的药物类别.
- 强调了解AE病理生理学对临床管理的重要性.
主要方法:
- 对BK代谢和药物诱导的AE现有文献的审查.
- 分析不同药物类别影响BK通路的机制.
- 药物作用与AE发展的相关性.
主要成果:
- ACE 抑制剂和 neprilysin 抑制剂会影响 BK 代谢,从而增加 AE 的风险.
- DPP-IV 抑制剂减少了 BK 和物质 P 的分解.
- 血管激素受体抑制剂,血栓抑制剂和他类药物也可能触发BK介导的AE.
结论:
- BK代谢的失调是药物诱导的AE的核心,而没有疹.
- 了解这些机制对于预防和治疗AE至关重要.
- 针对BK途径提供了潜在的治疗策略.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
692
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
692
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Antihypertensive Drugs: Angiotensin II Receptor Blockers
780
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
780
Antihypertensive Drugs: Direct Renin Inhibitors
684
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
684
Antihypertensive Drugs: Action of β1 Blockers
483
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
483
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
890
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
890


